exRNAdisease

Entry Detail

---



General Information

Database ID: exR0085017 RNA Name: ZNF512B RNA Type: mRNA Chromosome: chr20 Starnd: - Coordinate: Start Site(bp): 63956704 End Site(bp): 63969930 External Links: ENSG00000196700

Disease Information

Disease Name: Fragile X Syndrome Disease Category: Congenital, Hereditary, and Neonatal Diseases and Abnormalities MeSH ID: D005600 Type: Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities Alias: Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID: GSE83556 Description: Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions Experimental Design: Disease vs Control Case Disease Type: Fragile X Syndrome Case Disease SubType: NA Case Sample: Fragile X Syndrome Control Sample: Normal Number of Case: 22 Number of Control: 18 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABHD10 chr3 111979010 111993368 + ADCY6 chr12 48766194 48789037 - AFDN chr6 167826922 167972023 + miRNA targets: miRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa-miR-148a-3p chr7 25949922 25949943 - hsa-miR-34a-5p chr1 9151735 9151756 - hsa-miR-146a-5p chr5 160485372 160485393 + hsa-miR-184 chr15 79209840 79209861 + hsa-miR-206 chr6 52144401 52144422 + hsa-miR-34c-5p chr11 111513451 111513473 + hsa-miR-378a-3p chr5 149732867 149732888 + hsa-miR-148b-3p chr12 54337278 54337299 + hsa-miR-449a chr5 55170586 55170607 - hsa-miR-146b-5p chr10 102436520 102436542 + hsa-miR-625-5p chr14 65471116 65471136 + hsa-miR-663a chr20 26208243 26208264 - hsa-miR-449b-5p chr5 55170706 55170727 - hsa-miR-654-5p chr14 101040234 101040255 + hsa-miR-1294 chr5 154347153 154347174 + circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005562.1 chr17 30576464 30672789 + AC009133.5 chr16 29808679 29812227 + AD000090.1 chr19 35557956 35581954 + Display:

Experiment Detail

GEO ID: GSE83556 Sample Source: Amniotic Fluid Source Fraction: Supernatant Platform: GPL570 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 17063 Sample treatment protocol: RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min). RNA Extract protocol: All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water. RNA library preparation protocol: RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference

PMID: NA Title: NA Author: NA Journal: NA Description: NA